Can biotech stocks beat the S&P 500?
We don't tell you every stock is a buy. But our research occasionally uncovers hidden gems. From our inception through March 1, 2024, stocks that earned our coveted Asymmetric Opportunity label delivered an average return of 44.0% and outperformed the S&P 500 by 21.7%.